Change of Advisor

22^nd Feb 2017

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces the appointment of Nplus1 Singer Advisory LLP ("N+1 Singer") as Nominated Adviser and sole Broker to the Company with immediate effect.

EKF Diagnostics Holdings plc Julian Baines, CEO Richard Evans, Finance Director and COO	00 44 29 2071 0570
N+1 Singer Alex Price / Alex Laughton-Scott	00 44 20 7496 3000
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

HbA1c testing at the point-of-care: Comparison against international quality standards

Nurses from the University of Arkansas Study Abroad program using DiaSpect Tm in Ghana

EKF at Medic East Africa - Nairobi 2018

EKF to highlight new Glycated Albumin assay kit at AACC 2018

EKF Diagnostics, the global in vitro diagnostics company, announces that on Booth #3880 at the AACC 2018 Clinical Lab Expo it will be highlighting a new Stanbio Chemistry Glycated Albumin (GA) assay kit and its newly FDA cleared DiaSpect Tm hemoglobin point of care analyzer. Located in Chicago, IL, from July 31^st to August 2^nd, AACC is the world’s largest exposition for clinical laboratory products and services.